Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
50%(4 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_3
2
15%
Ph phase_1
2
15%
Ph not_applicable
1
8%
Ph phase_2
4
31%
Ph phase_4
3
23%

Phase Distribution

2

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
2(16.7%)
Phase 4Post-market surveillance
3(25.0%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

8 of 12 finished

Non-Completion Rate

33.3%

4 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(8)
Terminated(4)

Detailed Status

Completed8
Withdrawn2
Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 24 (33.3%)
Phase 32 (16.7%)
Phase 43 (25.0%)
N/A1 (8.3%)

Trials by Status

completed862%
not_yet_recruiting18%
withdrawn215%
terminated215%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency

NCT06117982
not_yet_recruiting

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

NCT06504901
terminatedphase_2

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165
completedphase_4

Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia

NCT02816112
withdrawnphase_2

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

NCT02682953
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06117982Phase 2

The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency

Completed
NCT06504901

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not Yet Recruiting
NCT00074165Phase 2

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Terminated
NCT02816112Phase 4

Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia

Completed
NCT02682953Phase 2

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

Withdrawn
NCT02816164Phase 4

A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia

Completed
NCT02762799Phase 1

Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®

Completed
NCT02489500Phase 3

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

Terminated
NCT01181271Phase 2

Tandem Auto-Allo Transplant for Lymphoma

Completed
NCT03023774Not Applicable

Use of Gcsf in Patients With Recurrent Ivf/Icsi Failure

Completed
NCT02725086Phase 1

Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult Volunteers

Completed
NCT02408991Phase 4

Use Art-assist and Neupogen to Treat Chronic Limb Ischemia

Withdrawn
NCT00776165Phase 3

Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13